eClinical Technology and Industy News

Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron

Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study

Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, including Omicron

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.

In the first study, Vaxart will test the activity of its Phase II COVID-19 oral vaccine candidate against Omicron by analyzing mucosal and serum samples from subjects to whom the vaccine was administered in Vaxart’s current COVID-19 vaccine Phase II trials, Dr. Sean Tucker, Vaxart’s Chief Scientific Officer and founder, said.

In the second study, Vaxart will conduct an animal Omicron challenge study to assess how its current Phase II COVID-19 vaccine candidate performs in comparison to an Omicron-specific vaccine candidate that Vaxart is developing, Dr. Tucker said.

Vaxart deliberately engineered its COVID-19 vaccine candidate to be cross-reactive against emerging variants based on Vaxart scientists’ early recognition of the risk of emerging variants of SARS-CoV-2. In May 2021, the Company announced Phase I clinical test results demonstrating that its vaccine candidate, VXA-CoV2-1, produced broad cross-reactive T cell and IgA responses against other, non-COVID coronaviruses.

“We expect that our COVID-19 vaccine candidates would be less affected by mutations in the receptor-binding domain of the S protein than vaccines that rely on a serum IgG response,” Dr. Tucker said.

Dr. Tucker also said that results from Vaxart’s Phase I clinical testing and earlier preclinical testing support Vaxart’s belief that its vaccine candidates should be reactive against Omicron.

“Our Phase I vaccine candidate was highly cross-reactive in human subjects against coronaviruses much more divergent than SARS-CoV-2 variants, and our preclinical research showed that our current Phase II vaccine candidate induced substantial cross-reactivity against multiple SARS-CoV-2 variants,” he said. “As a result, we expect that this vaccine candidate should also be able to respond to the Omicron variant.”

“As new variants have emerged it has become clear that we cannot win the fight against this pandemic with only the current generation injectable vaccines,” said Vaxart Chief Executive Officer Andrei Floroiu. “To win this fight we need better, next-generation vaccines that provide broader, cross-variant protection, which our vaccine has the potential to do by leveraging the power of mucosal immunity.”

Injectable vaccines primarily stimulate serum IgG responses, but Vaxart’s COVID-19 vaccine candidate has been shown to trigger mucosal IgA in the nose, mouth and lungs, where SARS-CoV-2 infection occurs.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?